About US
Contact us
-
FDA slaps a clinical hold on Achillion hep C drugShares of Achillion ($ACHN) skidded down 20% as the FDA put a clinical hold on itshepatitis Cdrug sovaprevir. Investigators had flagged a spike in liver enzymes--a classic sign of toxicity--among a gr2013/7/3
-
Chinese police corral GlaxoSmithKline employees in bribery probeChinese police rounded up GlaxoSmithKline employees in three cities as part of an investigation into "economic crimes," law enforcement there said in a statement. According to as-yet-unconfirmed repor2013/7/2
-
Private equity buyers eye offer for GlaxoSmithKline's drinks brandsPrivate equity firms Blackstone and Lion Capital are together eyeing an offer for GlaxoSmithKline's ($GSK) drinks brands Lucozade and Ribena. Up for sale as the U.K.-based drugmaker sheds lower-perfor2013/7/2
-
Merck KGaA sees U.S. as 'emerging market' for sales growthAnyone who follows the drug business knows that pharma companies big and not-so-much are aiming for growth in emerging markets. ButMerck KGaAhas a twist on that strategy: The German company sees the U2013/7/1
-
Pfizer, Bristol-Myers tout new VTE data on Eliquis, aiming for new useWhen is non-inferiority actually superior? When you're talking about new substitutes for the difficult-to-administerwarfarin. So, Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) happily announced today2013/7/1
-
Pfizer, Amgen eye $1B deal for Russian biosimilars developer BiocadRussianpharma dealmaking is heating up. On the heels of news thatPharmstandardis shopping its over-the-counter business, thebiosimilardeveloper Biocad is said to be entertaining offers from the likes2013/6/28
-
How to save money via adherence? Let us count the (possible) waysThat there's money to be saved on healthcare spending--and lots of it--is not in question. Exactly how to save that money through further generics use and better prescription adherence is what patient2013/6/28
-
India yanks Takeda's Actos on safety concernsWhy now? That's a fair question aboutIndia'smove to suspend the sale of three drugs, includingTakeda Pharmaceuticals'now-off-patent blockbuster,Actos. The country's health ministry also banned Analgin2013/6/27
-
Bayer, Boehringer eye big growth in expanding anticoagulant marketBlood-clot fighters are expected to grow faster than any other drugs over the next 6 years. Here are two reasons why: The U.K.'s cost-effectiveness watchdog gave final clearance toBayer'santicoagulant2013/6/27
-
Allergan hits skids on probability of early Restasis genericsAllergan is eyeing some earlygeneric competitionfor its $792 million drug Restasis. The FDA says it won't need a clinical trial for approval of copycat versions, meaning the treatment for chronic dry2013/6/26